caa a22 4500 469073888 CHVBK 20180323132929.0 cr unu---uuuuu 170328e19920701xx s 000 0 eng 10.1007/BF01789330 doi (NATIONALLICENCE)springer-10.1007/BF01789330 Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C [Elektronische Daten] [Shinya Arinaga, Nobuya Karimine, Kiyoshi Takamuku, Shigeru Nanbara, Hiroshi Inoue, Ryoji Abe, Daisuke Watanabe, Hideo Matsuoka, Hiroaki Ueo, Tsuyoshi Akiyoshi] Summary: On the basis of our clinical findings that the ability of cancer patients to generate lymphokine-activated killer cells became markedly augmented after mitomycin C administration, we designed a treatment regimen comprising mitomycin C 12 mg/m2, i.v. on day 1 and recombinant interleukin-2 700 U/m2 (8000 IU/kg), i.v. every 12 h from day 4 through day 8. The treatment course was repeated at almost 7-day intervals. Altogether 33 patients with advanced carcinoma, including mainly gastrointestinal carcinoma, were treated with this regimen. Of these, 10 had a partial response (PR) and 4 had a minor response (MR). Since eosinophil counts peaked 1 day after either the first or second course of the therapy, the posttreatment values were compared to each pretreatment level, with regard to the clinical antitumor response to this treatment. When patients who showed PR were defined as responders, absolute eosinophil counts and the percentages of eosinophils in responders after both the first and second courses of the therapy were significantly greater than each pretreatment value or the posttreatment level in nonresponders. Further, these findings were almost identical, when both PR and MR were considered to be a true remission and therefore patients who exhibited PR or MR were defined as responders, although the difference between posttreatment levels of eosinophils in responders and nonresponders was not significant at the second course. These results indicate that eosinophilia induced by this treatment correlates with the clinical response to this therapy. Springer-Verlag, 1992 Eosinophilia nationallicence Antitumor response nationallicence Interleukin-2 nationallicence Mitomycin C nationallicence Advanced carcinoma nationallicence Arinaga Shinya Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut Karimine Nobuya Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut Takamuku Kiyoshi Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut Nanbara Shigeru Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut Inoue Hiroshi Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut Abe Ryoji Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut Watanabe Daisuke Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut Matsuoka Hideo Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut Ueo Hiroaki Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut Akiyoshi Tsuyoshi Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut Cancer Immunology, Immunotherapy Springer-Verlag 35/4(1992-07-01), 246-250 0340-7004 35:4<246 1992 35 262 https://doi.org/10.1007/BF01789330 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01789330 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Arinaga Shinya Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut NATIONALLICENCE 700 1- Karimine Nobuya Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut NATIONALLICENCE 700 1- Takamuku Kiyoshi Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut NATIONALLICENCE 700 1- Nanbara Shigeru Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut NATIONALLICENCE 700 1- Inoue Hiroshi Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut NATIONALLICENCE 700 1- Abe Ryoji Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut NATIONALLICENCE 700 1- Watanabe Daisuke Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut NATIONALLICENCE 700 1- Matsuoka Hideo Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut NATIONALLICENCE 700 1- Ueo Hiroaki Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut NATIONALLICENCE 700 1- Akiyoshi Tsuyoshi Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 874, Beppu, Japan aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 35/4(1992-07-01), 246-250 0340-7004 35:4<246 1992 35 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer